

Pavel Moudry

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3103537/pavel-moudry-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

761
citations

8
h-index

10
g-index

10
ext. papers

1,031
ext. citations

14.6
avg, IF

3.92
L-index

#	Paper	IF	Citations
10	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017 , 552, 194-199	50.4	320
9	High speed of fork progression induces DNA replication stress and genomic instability. <i>Nature</i> , 2018 , 559, 279-284	50.4	221
8	Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. <i>Cell Cycle</i> , 2012 , 11, 1573-82	4.7	64
7	Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. <i>Aging</i> , 2019 , 11, 2512-2546	3.6	57
6	TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. <i>Journal of Cell Biology</i> , 2016 , 212, 281-8	7.3	47
5	Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells. <i>Cell Cycle</i> , 2018 , 17, 92-101	4.7	19
4	Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. <i>Journal of Proteomics</i> , 2017 , 162, 73-85	3.9	17
3	Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. <i>Oncotarget</i> , 2015 , 6, 10746-58	3.3	13
2	RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. <i>Cell Death and Differentiation</i> , 2021 ,	12.7	2
1	A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.. <i>Cell Death and Disease</i> , 2022 , 13, 203	9.8	1